NTRA News and Press, Natera Inc. From 09/07/23

Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the pricing of its underwritten public offering of 4,550,000 shares of its common stock at a price to the public of $55.00 per share. Closing of the offering is expected to occur on September 11, 2023, ...

2023-09-06 16:46:21 ET More on Natera Seeking Alpha’s Quant Rating on Natera Historical earnings data for Natera Financial information for Natera Natera: Strong Growth Amidst Profitability Challenges Natera, Inc. 2023 Q2 - Results - Earnings Ca...

Represents third covered indication for Prospera Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has received confirmation that its Prospera Lung donor-derived cfDNA (dd-cfDNA) transplant assessment test has met coverage require...

2023-08-15 09:25:20 ET Summary Natera specializes in cfDNA technology, achieving 31.9% revenue growth in Q2 2023 and raising their annual outlook. Despite strong growth, Natera faces challenges with profitability, annual cash burn, and existing debts. Considering growth prospe...

2023-08-14 08:15:00 ET Summary This article provides a dashboard with industry metrics in healthcare, then focus on the Global X Genomics & Biotechnology ETF. Pharmaceuticals/biotechnology and healthcare providers have fair value and quality scores. Healthcare equipment is...

2023-08-04 11:15:26 ET Shares of Natera (NASDAQ: NTRA) were soaring 18.7% higher at 11:04 a.m. ET on Friday. The big gain came after the DNA testing company announced its second-quarter results following the market close on Thursday. Natera reported Q2 revenue of $261.4 million,...

2023-08-04 10:09:12 ET Gainers: Alector ( ALEC ) +22% . OraSure Technologies ( OSUR ) +21% . Amneal Pharmaceuticals ( AMRX ) +20% . iRhythm Technologies ( IRTC ) +20% . Natera ( NTRA ) +16% . Losers: Mesoblast ( MESO ) ...

2023-08-03 22:08:04 ET Natera, Inc. (NTRA) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Michael Brophy – Chief Financial Officer Steve Chapman – Chief Executive Officer Solomon Moshkevich – General Manager-O...

2023-08-03 16:53:46 ET Natera press release ( NASDAQ: NTRA ): Q2 GAAP EPS of -$0.97 beats by $0.11 . Revenue of $261.4M (+31.9% Y/Y) beats by $19.87M . Outlook: Natera is raising its expectations for 2023 total revenue from $995 million to $1.015 billion to...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 2023. Recent Strategic and Financial Highlights Generated total revenues of $261.4 million in the second quarter of 2023, compared to $198.2 ...